VNDA — Vanda Pharmaceuticals Balance Sheet
0.000.00%
- $355.59m
- -$38.55m
- $192.64m
- 79
- 47
- 86
- 81
Annual balance sheet for Vanda Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 312 | 368 | 433 | 467 | 388 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 26.4 | 30 | 32.5 | 33.5 | 34.2 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 354 | 409 | 478 | 519 | 433 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 15 | 14.6 | 12.4 | 11 | 9.14 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 484 | 533 | 594 | 634 | 648 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 59.5 | 65.9 | 74.4 | 91.4 | 87.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 72.8 | 80.2 | 88.9 | 107 | 104 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 411 | 453 | 505 | 527 | 545 |
Total Liabilities & Shareholders' Equity | 484 | 533 | 594 | 634 | 648 |
Total Common Shares Outstanding |